ALVO vs. SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, ROIV, RVMD, and VRNA
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.
Alvotech vs.
Summit Therapeutics (NASDAQ:SMMT) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Summit Therapeutics received 307 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 58.58% of users gave Summit Therapeutics an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
Summit Therapeutics currently has a consensus target price of $37.40, suggesting a potential upside of 69.38%. Alvotech has a consensus target price of $18.00, suggesting a potential upside of 73.58%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than Summit Therapeutics.
4.6% of Summit Therapeutics shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Alvotech had 7 more articles in the media than Summit Therapeutics. MarketBeat recorded 23 mentions for Alvotech and 16 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.38 beat Alvotech's score of 0.18 indicating that Summit Therapeutics is being referred to more favorably in the media.
Summit Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Summit Therapeutics' return on equity.
Summit Therapeutics has a beta of -1.06, indicating that its stock price is 206% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.
Alvotech has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
Summary
Summit Therapeutics beats Alvotech on 10 of the 19 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Alvotech Competitors List
Related Companies and Tools
This page (NASDAQ:ALVO) was last updated on 6/11/2025 by MarketBeat.com Staff